跳至主要内容
临床试验/CTRI/2012/03/002508
CTRI/2012/03/002508已完成3 期

Evaluation of efficacy and safety of fixed dose combination of a proton pump inhibitor and a dopamine (DA2) antagonist in the treatment of gastroesophageal reflux disease (GERD): a randomized, open label, comparative, multicentric study. - GERD

Sun Pharmaceutical Industries Ltd0 个研究点目标入组 200 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Male or female patients aged between 18-70 years.
  • 2.Patients with GERD (Gastro esophageal Reflux Disease).
  • 3.Patients willing to give informed consent.

排除标准

  • 1.Pregnant, lactating women or women of childbearing age who are not using an acceptable method of birth control.
  • 2.Patients with peptic ulcer or Zollinger-Ellison syndrome.
  • 3.Patients with previous surgery of gastrointestinal tract excluding appendectomy, cholecystectomy and polypectomy.
  • 4.Patients with other diseases or conditions such as scleroderma, pancreatitis, cancer, Parkinsonâ??s disease, epilepsy, mania and inflammatory bowel disease.
  • 5.Patients with any severe illnesses (hepatic, renal, cardiac).
  • 6.Patients with uncontrolled diabetes, hypertension, clotting disorder.
  • 7.History of heavy smoking ( > 20 cigarettes per day).
  • 8.Hypersensitive to either esomeprazole or levosulpiride.
  • 9.Recent (in the past two years) drug dependence or abuse.
  • 10.History of non-compliance to medical regimens or those patients unwilling to comply with the study protocol.

研究者

相似试验